DR

Dheeraj Reddy Kambam

Active Director Designated Partner DIN 10286384
DIN 10286384 First appointment Aug 2023 Primary industry Paper
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Dheeraj Reddy Kambam

Data last updated:

Dheeraj Reddy Kambam is a Designated Partner at Aqgen Pharma Llp (since 2023). The company operates in Paper.

DIN 10286384
Primary Designation Designated Partner
Industry Paper
First Appointment 21 Aug 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Aqgen Pharma Llp ACC-5526
Designated Partner21 Aug 20232023Active

Board colleagues of Dheeraj Reddy Kambam

NameDINCompanyDesignation
Divyabhishek Reddy Kambham09354582Aqgen Pharma LlpDesignated Partner
Nikitha Reddy Penubaka10178290Aqgen Pharma LlpDesignated Partner

Directorship timeline

Open interactive timeline →
Aqgen Pharma Llp
Premium access

Shareholding and investment profile for Dheeraj Reddy Kambam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Dheeraj Reddy Kambam

Dheeraj Reddy Kambam currently holds 1 directorship: Aqgen Pharma Llp (Designated Partner, since 21 Aug 2023).

Dheeraj Reddy Kambam was first appointed on 21 Aug 2023 as Designated Partner at Aqgen Pharma Llp.

The current boards of Dheeraj Reddy Kambam's companies include Divyabhishek Reddy Kambham (Aqgen Pharma Llp), Nikitha Reddy Penubaka (Aqgen Pharma Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available